Skip to main content

Voyager Therapeutics, Inc.

VYGR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001640266

No open-market purchases or sales by Voyager Therapeutics, Inc. insiders were filed in the last 90 days; 135 institutions reported holding it in 13F filings for Q2 2026, worth $122.7M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Voyager Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Voyager Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Voyager Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Scangos George ADirector–Jun 11, 20261
Geraghty James ADirector–Jun 11, 20261
Pierce GlennDirector16,788Jun 11, 20261
Higgins Michael JDirector31,314Jun 11, 20261
Mackey Catherine JDirector–Jun 11, 20261
Hyman StevenDirector–Jun 11, 20261
Colon GraceDirector–Jun 11, 20261
Vitale NancyDirector–Jun 11, 20261
Onyia JudeDirector–Jun 11, 20261
Sandrock AlfredPresident and CEO472,549Apr 3, 20265
Shiferman Gregory L.SVP and General Counsel50,000Apr 3, 20262
Jorgensen Nathan D.Chief Financial Officer151,416Feb 26, 20263
Swartz RobinCOO & CBO199,738Feb 26, 20264
Carter Todd AlfredChief Scientific Officer145,718Feb 26, 20264
Ferguson TobyChief Medical Officer183,914Feb 10, 20261
Fahey Sandell JacquelynChief Legal Officer123,143Feb 24, 20250
Pfreundschuh Peter P.Chief Financial Officer175,669Feb 22, 20240
Hesslein Robert W.Senior VP & General Counsel102,200Mar 22, 20230
Neurocrine Biosciences Inc10% Owner8,575,316Feb 24, 20230
Tepper Robert I10% Owner3,185,291Feb 6, 20230
Third Rock Ventures III, L.P.10% Owner3,185,291Feb 6, 20230
TRV GP III, LLC10% Owner3,185,291Feb 6, 20230
Third Rock Ventures GP III, L.P.10% Owner3,185,291Feb 6, 20230
EcoR1 Capital, LLC10% Owner3,851,507IndirectJan 11, 20230
Burek JulieVP, Finance52,458Mar 23, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 3, 2026 (view filing)Apr 21 daySandrock AlfredPresident and CEOSSale−11.5K$3.87−$44.5K−2.4%472.5K after10b5-1
Feb 26, 2026 (view filing)Feb 242 daysSwartz RobinCOO & CBOSSale−6.46K$3.77−$24.3K−3.1%199.7K after10b5-1
Feb 26, 2026 (view filing)Feb 242 daysSandrock AlfredPresident and CEOSSale−14.2K$3.79−$53.8K−2.8%484.1K after10b5-1
Feb 26, 2026 (view filing)Feb 242 daysJorgensen Nathan D.Chief Financial OfficerSSale−4.67K$3.77−$17.6K−3.0%151.4K after10b5-1
Feb 26, 2026 (view filing)Feb 242 daysCarter Todd AlfredChief Scientific OfficerSSale−4.17K$3.76−$15.7K−2.8%145.7K after10b5-1
Feb 20, 2026 (view filing)Feb 182 daysSwartz RobinCOO & CBOSSale−3.88K$3.44−$13.4K−1.8%206.2K after10b5-1
Feb 20, 2026 (view filing)Feb 182 daysCarter Todd AlfredChief Scientific OfficerSSale−3.30K$3.44−$11.4K−2.2%149.9K after10b5-1
Feb 20, 2026 (view filing)Feb 182 daysSandrock AlfredPresident and CEOSSale−11.7K$3.41−$40.0K−2.3%498.3K after10b5-1
Feb 11, 2026 (view filing)Feb 101 daySwartz RobinCOO & CBOSSale−4.57K$3.85−$17.6K−2.1%210.1K after
Feb 11, 2026 (view filing)Feb 101 daySandrock AlfredPresident and CEOSSale−12.2K$3.78−$46.1K−2.3%510.0K after
Feb 11, 2026 (view filing)Feb 101 dayCarter Todd AlfredChief Scientific OfficerSSale−3.52K$3.85−$13.6K−2.2%153.2K after
Oct 7, 2025 (view filing)Oct 34 daysJorgensen Nathan D.Chief Financial OfficerSSale−7.67K$4.78−$36.6K−5.8%123.8K after10b5-1
Aug 20, 2025 (view filing)Aug 182 daysFerguson TobyChief Medical OfficerSSale−19.0K$3.73−$70.9K−12.0%138.9K after
Apr 4, 2025 (view filing)Apr 22 daysFerguson TobyChief Medical OfficerSSale−10.1K$3.43−$34.6K−6.0%157.9K after
Apr 4, 2025 (view filing)Apr 22 daysSandrock AlfredPresident and CEOSSale−10.9K$3.43−$37.3K−2.5%430.9K after
Feb 24, 2025 (view filing)Feb 204 daysCarter Todd AlfredChief Scientific OfficerSSale−3.31K$4.26−$14.1K−4.1%77.7K after
Feb 24, 2025 (view filing)Feb 204 daysSandrock AlfredPresident and CEOSSale−11.7K$4.24−$49.6K−3.8%296.8K after
Feb 24, 2025 (view filing)Feb 204 daysSwartz RobinCOO & CBOSSale−3.89K$4.25−$16.5K−3.8%98.4K after
Feb 12, 2025 (view filing)Feb 111 dayCarter Todd AlfredChief Scientific OfficerSSale−5.41K$4.45−$24.1K−6.3%81.0K after
Feb 12, 2025 (view filing)Feb 111 daySwartz RobinCOO & CBOSSale−6.95K$4.45−$30.9K−6.4%102.3K after
Feb 12, 2025 (view filing)Feb 111 daySandrock AlfredPresident & CEOSSale−16.6K$4.45−$74.1K−5.1%308.5K after
Feb 12, 2025 (view filing)Feb 111 dayFahey Sandell JacquelynChief Legal OfficerSSale−4.36K$4.45−$19.4K−5.1%81.6K after
Jan 15, 2025 (view filing)Jan 141 daySwartz RobinCOO & CBOSSale−3.09K$5.09−$15.7K−2.7%109.2K after
Jan 15, 2025 (view filing)Jan 141 dayCarter Todd AlfredChief Scientific OfficerSSale−1.19K$5.13−$6.11K−1.4%86.4K after
Dec 26, 2024 (view filing)Dec 233 daysSwartz RobinCOO&CBOSSale−6.50K$5.65−$36.7K−5.5%112.3K after
Oct 3, 2024 (view filing)Oct 21 dayFahey Sandell JacquelynChief Legal OfficerSSale−6.00K$5.82−$34.9K−6.5%86.0K after
Apr 3, 2024 (view filing)Apr 21 daySwartz RobinChief Operating OfficerSSale−1.36K$9.88−$13.4K−1.1%117.0K after
Apr 3, 2024 (view filing)Apr 21 daySandrock AlfredPresident and CEOSSale−12.1K$9.86−$119.5K−3.6%322.8K after
Feb 22, 2024 (view filing)Feb 211 daySwartz RobinChief Operating OfficerSSale−3.97K$7.45−$29.5K−3.2%118.4K after
Feb 22, 2024 (view filing)Feb 211 daySandrock AlfredPresident and CEOSSale−13.0K$7.46−$97.2K−3.7%335.0K after
Feb 22, 2024 (view filing)Feb 211 dayPfreundschuh Peter P.Chief Financial OfficerSSale−3.76K$7.46−$28.1K−2.1%175.7K after
Feb 22, 2024 (view filing)Feb 20-212 daysCarter Todd AlfredChief Scientific OfficerSSale−3.97K$7.50−$29.8K−4.3%87.6K after2 lots
Jan 19, 2024 (view filing)Jan 172 daysSwartz RobinChief Operating OfficerSSale−2.54K$7.15−$18.2K−3.4%72.3K after
Jan 19, 2024 (view filing)Jan 172 daysCarter Todd AlfredChief Scientific OfficerSSale−1.27K$7.18−$9.09K−2.3%53.1K after
Oct 5, 2023 (view filing)Oct 32 daysPfreundschuh Peter P.Chief Financial OfficerSSale−13.6K$6.99−$94.8K−8.3%149.4K after
Sep 18, 2023 (view filing)Sep 153 daysCarter Todd AlfredChief Scientific OfficerSSale−10.5K$8.16−$85.7K−16.2%54.4K after10b5-1
Jul 10, 2023 (view filing)Jul 64 daysCarter Todd AlfredChief Scientific OfficerSSale−5.50K$10.80−$59.4K−8.4%59.9K after10b5-1
Jul 5, 2023 (view filing)Jun 305 daysCarter Todd AlfredChief Scientific OfficerSSale−5.00K$11.41−$57.0K−7.1%65.4K after10b5-1
Apr 5, 2023 (view filing)Apr 32 daysSandrock AlfredPresident and CEOSSale−7.44K$7.83−$58.2K−3.3%214.6K after
Apr 5, 2023 (view filing)Apr 32 daysSwartz RobinChief Operating OfficerSSale−1.26K$7.83−$9.86K−1.7%71.6K after
Mar 22, 2023 (view filing)Mar 202 daysCarter Todd AlfredChief Scientific OfficerSSale−2.19K$7.76−$17.0K−3.2%65.4K after
Mar 22, 2023 (view filing)Mar 202 daysSwartz RobinChief Operating OfficerSSale−3.65K$7.76−$28.4K−4.8%72.9K after
Mar 22, 2023 (view filing)Mar 202 daysHesslein Robert W.Senior VP & General CounselSSale−4.41K$7.76−$34.2K−4.1%102.2K after
Mar 17, 2023 (view filing)Mar 152 daysSwartz RobinChief Operating OfficerSSale−15.4K$8.20−$126.1K−16.7%76.5K after
Feb 24, 2023 (view filing)Feb 231 dayNeurocrine Biosciences Inc10% OwnerPPurchase+4.40M$8.88+$39.0M+105.2%8.58M after
Feb 22, 2023 (view filing)Feb 175 daysHesslein Robert W.Senior VP & General CounselSSale−3.30K$7.45−$24.6K−3.0%106.6K after
Feb 22, 2023 (view filing)Feb 175 daysCarter Todd AlfredChief Scientific OfficerSSale−738$7.45−$5.50K−1.1%67.6K after
Feb 15, 2023 (view filing)Feb 132 daysCarter Todd AlfredChief Scientific OfficerSSale−797$7.67−$6.11K−2.3%34.3K after
Feb 15, 2023 (view filing)Feb 132 daysHesslein Robert W.Senior VP & General CounselSSale−2.87K$7.67−$22.0K−2.5%109.9K after
Feb 1, 2023 (view filing)7:26 PM ETJan 30-Feb 12 daysTepper Robert I and 3 others10% OwnerSSale−388.6K$9.23−$3.59M−7.7%4.69M after3 lots